NCT00594815 · OUTCOME

Progression Free Survival

Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma · Source last updated 2017-04-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: percentage of participants
Interval / dispersion: 95% Confidence Interval
Time frame: 2 Years

What was measured

Overall Progression Free Survival at 2 years

Groups in this outcome

Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma

Cytarabine, Leucovorin, Methotrexate, Procarbazine, Rituximab, Vincristine: Immunochemotherapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma	52

Reported measurements

Source class 1

Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma	57	Not reported	44	71	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
44
upper Limit
71
value
57

denoms

counts
group Id
OG000
value
52
units
Participants

description

Overall Progression Free Survival at 2 years

dispersion Type

95% Confidence Interval

groups

description
Cytarabine, Leucovorin, Methotrexate, Procarbazine, Rituximab, Vincristine: Immunochemotherapy
id
OG000
title
Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma

param Type

NUMBER

reporting Status

POSTED

time Frame

2 Years

title

Progression Free Survival

type

PRIMARY

unit Of Measure

percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice